What is Guided Therapeutics Debt-to-Equity?
Guided Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.39 Mil. Guided Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.67 Mil. Guided Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-3.81 Mil.
Guided Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.54.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Guided Therapeutics's Debt-to-Equity or its related term are showing as below:
GTHP'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.79 Med: -0.42 Max: -0.24
Current: -0.54
During the past 13 years, the highest Debt-to-Equity Ratio of Guided Therapeutics was -0.24. The lowest was -0.79. And the median was -0.42.
Guided Therapeutics Debt-to-Equity Historical Data
The historical data trend for Guided Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics Debt-to-Equity Chart
|
Guided Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
-0.36 |
-0.41 |
-0.53 |
-0.79 |
-0.54 |
|
Guided Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.79 |
-0.74 |
-0.63 |
-0.57 |
-0.54 |
Competitive Comparison of Guided Therapeutics's Debt-to-Equity
For the Medical Devices subindustry, Guided Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guided Therapeutics's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Guided Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Guided Therapeutics's Debt-to-Equity falls into.
Guided Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Guided Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Guided Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guided Therapeutics (Guided Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
5835 Peachtree Corners East, Suite B, Norcross, GA, USA, 30092
Guided Therapeutics Inc is a medical technology company. It is engaged in developing medical devices that have the potential to improve healthcare. Its primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The company generates revenue from the sale of medical devices.
Executives
| John E Imhoff |
director, 10 percent owner |
P.O. BOX 31083, SEA ISLAND GA 31561 |
| Alan Grujic |
director |
349 FORBES AVE, SAN RAFAEL CA 94901 |
| Michael C James |
director |
2040 MAIN STREET, SUITE 225, IRVINE CA 92614 |
| Richard P. Blumberg |
director |
2357 HOBART AVENUE S.W., SEATTLE WA 98116 |
| Lynne H Imhoff |
10 percent owner |
2716 SOUTH ROCKFORD ROAD, TULSA OK 74114 |
| Gene S Cartwright |
officer: Chief Executive Officer |
4088 COMMERCIAL AVE, NORTHBROOK IL 60062 |
| Parsons & Whittemore Enterprises Corp. |
10 percent owner |
4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
| George F. Landegger 2010 10-year Grat |
10 percent owner |
4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
| George F Landegger |
10 percent owner |
4 INTERNATIONAL DRIVE, RYE BROOK, NEW YORK NY 10573 |
| Whittemore Collection Ltd |
10 percent owner |
4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
| George F. Landegger 2010 5-year Grat |
10 percent owner |
4 INTERNATIONAL DRIVE, RYE BROOK NY 10573 |
| Linda Rosenstock |
director |
5995 PLAZA DRIVE, MAIL STOP CY20-103, CYPRESS CA 90630 |
| Jonathan M Niloff |
director |
C/O MATRITECH, INC., 330 NEVADA STREET, NEWTON MA 02460 |
| Ronald W Allen |
director |
P O BOX 1734, ATLANTA GA 30301 |
| Shabbir Bakir Bambot |
officer: VP of R & D |
4955 AVALON RIDGE PARKWAY, SUITE 300, NORCROSS GA 30071 |
Guided Therapeutics (Guided Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GTHP has been successfully added to your